Rani Therapeutics Holdings（RANI）株式概要
Rani Therapeutics Holdings, Inc.は、臨床段階のバイオセラピューティクス企業として、米国で痛みを伴う注射に代わる生物製剤や薬剤の経口投与を可能にする技術に焦点を当て、患者、医師、医療システム向けに事業を展開している。 詳細
RANI Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Rani Therapeutics Holdings, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$0.90 |
| 52週高値 | US$3.87 |
| 52週安値 | US$0.42 |
| ベータ | 0.80 |
| 1ヶ月の変化 | 16.05% |
| 3ヶ月変化 | -2.05% |
| 1年変化 | 97.08% |
| 3年間の変化 | -79.10% |
| 5年間の変化 | n/a |
| IPOからの変化 | -91.85% |
最新ニュース
ナラティブ更新 • Jul 01
RANI: Cash Raise And Nasdaq Compliance Efforts Will Drive Future Upside
Analysts have reduced their price target for Rani Therapeutics Holdings from $9.25 to $7.50, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E levels in their valuation models. What’s in the News for Rani Therapeutics Holdings Rani Therapeutics Holdings received a notice from Nasdaq on May 11, 2026, that its Class A common stock no longer meets the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Global Market, with a 180 day window until November 9, 2026, to regain compliance.
ナラティブ更新 • Jun 17
RANI: Follow-On Offering Will Support Obesity Capsule Trial Progress
Analysts have reaffirmed their $11.00 price target on Rani Therapeutics Holdings, citing updated assumptions for revenue growth, profit margins and future P/E that are broadly in line with prior estimates. What’s in the News for Rani Therapeutics Holdings Rani Therapeutics Holdings filed a follow-on equity offering totaling approximately US$20.0 million in Class A common stock and pre-funded warrants, including 12,476,637 Class A shares at US$1.07 per share and 6,214,953 pre-funded warrants at US$1.0699 per warrant, according to company filings.ナラティブ更新 • Jun 02
RANI: Obesity Capsule Trial Progress Will Offset Listing And Leadership Uncertainty
Analysts are keeping their price target for Rani Therapeutics Holdings steady at $11.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that refine rather than materially change their overall view. What's in the News Rani Therapeutics Holdings filed a follow-on equity offering of approximately US$20.0 million, including 12,476,637 shares of Class A common stock at US$1.07 per share and 6,214,953 pre-funded warrants at US$1.0699 per warrant, with a stated discount of US$0.0642 per security, in a registered direct offering.Recent updates
ナラティブ更新 • Jul 01
RANI: Cash Raise And Nasdaq Compliance Efforts Will Drive Future Upside
Analysts have reduced their price target for Rani Therapeutics Holdings from $9.25 to $7.50, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E levels in their valuation models. What’s in the News for Rani Therapeutics Holdings Rani Therapeutics Holdings received a notice from Nasdaq on May 11, 2026, that its Class A common stock no longer meets the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Global Market, with a 180 day window until November 9, 2026, to regain compliance.ナラティブ更新 • Jun 17
RANI: Follow-On Offering Will Support Obesity Capsule Trial Progress
Analysts have reaffirmed their $11.00 price target on Rani Therapeutics Holdings, citing updated assumptions for revenue growth, profit margins and future P/E that are broadly in line with prior estimates. What’s in the News for Rani Therapeutics Holdings Rani Therapeutics Holdings filed a follow-on equity offering totaling approximately US$20.0 million in Class A common stock and pre-funded warrants, including 12,476,637 Class A shares at US$1.07 per share and 6,214,953 pre-funded warrants at US$1.0699 per warrant, according to company filings.ナラティブ更新 • Jun 02
RANI: Obesity Capsule Trial Progress Will Offset Listing And Leadership Uncertainty
Analysts are keeping their price target for Rani Therapeutics Holdings steady at $11.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that refine rather than materially change their overall view. What's in the News Rani Therapeutics Holdings filed a follow-on equity offering of approximately US$20.0 million, including 12,476,637 shares of Class A common stock at US$1.07 per share and 6,214,953 pre-funded warrants at US$1.0699 per warrant, with a stated discount of US$0.0642 per security, in a registered direct offering.ナラティブ更新 • Apr 27
RANI: Obesity Capsule Trial Progress Will Support Strong Future Upside Potential
Analysts have kept their $11.00 price target for Rani Therapeutics Holdings unchanged, citing a balance between slightly adjusted revenue growth, profit margin expectations, and a modestly lower future P/E assumption. Valuation Changes Fair Value: $11.00 remains unchanged, indicating no adjustment to the core valuation estimate.ナラティブ更新 • Apr 12
RANI: Obesity Capsule Trial Progress Will Drive Stronger Future Upside Potential
Analysts maintained their $11.00 price target for Rani Therapeutics Holdings, citing only marginal tweaks in their long term growth and P/E assumptions rather than a change in their overall view of the company. Valuation Changes Fair Value: $11.00 remains unchanged, with no adjustment to the headline valuation figure.
新しいナラティブ • Mar 31
Early Clinical Uncertainty And Cash Runway Risk Will Shape Platform Potential Later
Catalysts About Rani Therapeutics Holdings Rani Therapeutics Holdings is a clinical stage biotherapeutics company focused on enabling oral delivery of biologic drugs through its RaniPill capsule platform. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Mar 29
RANI: Obesity Capsule Trial Progress Will Drive Stronger Future Upside Potential
Analysts have kept their price target for Rani Therapeutics Holdings steady at $11.00, reflecting updated assumptions for revenue growth, profit margin, and future P/E that broadly balance each other out in their models. What's in the News Rani Therapeutics started a Phase 1 clinical trial of RT-114, an orally administered RaniPill capsule containing the GLP-1/GLP-2 dual agonist PG-102, for the treatment of obesity (Key Developments).分析記事 • Mar 28
We're Hopeful That Rani Therapeutics Holdings (NASDAQ:RANI) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...ナラティブ更新 • Mar 10
RANI: Obesity Capsule Trial Progress Will Support A More Optimistic Outlook
Analysts have kept their $11.00 price target for Rani Therapeutics Holdings unchanged, citing updated assumptions about very large revenue growth expectations, a stronger projected profit margin near 21%, and a higher anticipated future P/E multiple as key drivers within their models. What's in the News Rani Therapeutics started a Phase 1 clinical trial for RT-114, an oral RaniPill capsule containing PG-102, to assess safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics in obesity treatment (Key Developments).ナラティブ更新 • Feb 24
RANI: Obesity Capsule Trial Progress Will Support A Stronger Outlook
Analysts have kept their $11.00 price target for Rani Therapeutics Holdings unchanged, citing largely steady assumptions around the discount rate, long-term revenue growth, profit margin, and future P/E as reasons to maintain their existing view. What's in the News Rani Therapeutics and ProGen began a Phase 1 clinical trial for RT-114, an oral RaniPill capsule containing PG-102, a GLP-1/GLP-2 dual agonist, for potential obesity treatment (company announcement).ナラティブ更新 • Feb 09
RANI: Obesity Capsule Trial Progress Will Support A Stronger Outlook
Analysts kept their fair value estimate for Rani Therapeutics Holdings steady at US$11.00, citing offsetting tweaks to key assumptions such as a slightly higher discount rate, a modestly different revenue growth outlook, a small adjustment to projected profit margins, and a marginally lower future P/E. What's in the News Rani Therapeutics Holdings started a Phase 1 clinical trial of RT-114, an orally administered RaniPill capsule containing PG-102, a GLP-1/GLP-2 dual agonist being developed for obesity, to assess safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics in single and multiple dosing.ナラティブ更新 • Jan 25
RANI: Obesity Trial Progress And Index Inclusion Will Support A Stronger Outlook
Analysts have kept their US$11.00 price target for Rani Therapeutics Holdings unchanged, citing only fine tuned inputs in discount rate, revenue growth, profit margin and future P/E assumptions that collectively do not shift their overall valuation view. What's in the News Rani Therapeutics and ProGen began a Phase 1 clinical trial of RT-114, an oral RaniPill capsule containing the GLP-1/GLP-2 dual agonist PG-102, to assess safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics in obesity treatment (Key Developments).ナラティブ更新 • Jan 11
RANI: Future Obesity Trial Progress Will Support A Stronger Bullish Outlook
Analysts have raised their fair value estimate for Rani Therapeutics Holdings from US$9.00 to US$11.00. They cite updated assumptions on revenue growth, profit margin and a higher future P/E multiple as the main factors behind the new price target.ナラティブ更新 • Dec 26
RANI: Collaboration With Chugai And Cash Infusion Will Drive Future Upside
Analysts have nudged their price target for Rani Therapeutics Holdings slightly higher to 9.25 dollars, reflecting modestly improved long term growth and profitability assumptions despite largely unchanged valuation inputs. What's in the News Rani Therapeutics was added to the NASDAQ Biotechnology Index, increasing its visibility among biotech investors (Index Constituent Adds).ナラティブ更新 • Dec 11
RANI: Licensing Deal And Capital Raise Will Support Future Platform Upside
Analysts have modestly reaffirmed their outlook on Rani Therapeutics Holdings, keeping the price target effectively unchanged at approximately 9.25 dollars. They continue to view the company’s long term revenue growth and margin profile as supportive of its elevated future valuation multiple.ナラティブ更新 • Nov 27
RANI: Recent Licensing Agreement Will Drive Platform Expansion and Revenue Potential
Analysts have lowered their price target for Rani Therapeutics Holdings from $9.50 to $9.25. They cited updated estimates of growth and profit margin impacts on future valuation.Seeking Alpha • Nov 05
Rani Therapeutics: Oral Biologics Vision Still Has Early-Stage Risks
Summary Rani Therapeutics Holdings, Inc. targets a new potential oral delivery of biologic drugs via the RaniPill. This could eventually replace injections and improve patient adherence. Their pipeline has RT-102 (osteoporosis), RT-111 (psoriasis), and RT-114 (obesity with ProGen). Interestingly, RANI anticipates initiating RT-114’s Phase 1 trials during 2H2025. So, their IP remains clearly in the very early stages for now. Still, their partnership with Chugai added much upfront cash payments and up to $175 million milestone payments. Overall, RANI stock still appears somewhat overvalued after the recent equity raises. And their IP is highly speculative. So, I feel a neutral Hold makes sense for now. Read the full article on Seeking Alphaナラティブ更新 • Nov 04
RANI: Future Pharma Partnership Will Unlock Major Deal Value Uplift
Analysts have raised their price target for Rani Therapeutics Holdings from $9.00 to $9.50, citing modest adjustments in future earnings expectations and profit margin outlook. What's in the News Rani Therapeutics Holdings announced it will present preclinical data on its RaniPill capsule at ObesityWeek 2025.ナラティブ更新 • Oct 21
Analysts Raise Rani Therapeutics Price Target Following Chugai Deal and Valuation Update
Analysts have increased their price target for Rani Therapeutics Holdings from $7.75 to $9.00. They cite recalibrated growth projections and adjusted profit expectations as key factors behind the change.ナラティブ更新 • Aug 15
RT-114 And Pill Technology Will Transform Obesity Treatments
Rani Therapeutics Holdings’ lower future P/E and declining net profit margin highlight reduced growth expectations, which is reflected in the consensus price target holding steady at $7.75. What's in the News Filed a $2.99 million follow-on equity offering via registered direct offering, including Class A common stock and pre-funded warrants at significant discount.
新しいナラティブ • Apr 09
RT-114 And Pill Technology Will Transform Obesity Treatments
RaniPill technology and RT-114 partnership position Rani Therapeutics to capture significant market share and boost future revenue.分析記事 • Feb 07
Is Rani Therapeutics Holdings (NASDAQ:RANI) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jul 16
Does Rani Therapeutics Holdings (NASDAQ:RANI) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Mar 20
Is Rani Therapeutics Holdings (NASDAQ:RANI) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Aug 08
Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development
Rani Therapeutics (NASDAQ:RANI) enters a loan agreement with Avenue Venture Opportunities Fund for up to $45M of funding. This financing is expected to support the continued advancement of the RaniPill platform and ongoing clinical development of the company’s drug pipeline. Under the loan agreement, company will receive $15M of the initial $30M tranche at closing, with the remaining $15M available for draw at the company’s discretion in Q4 2022. Company has the right to request an additional $15M of funds in the future if certain conditions and milestones are met. Interest at a variable rate equal to the greater of (1) prime, plus 5.6% and (2) 10.35%分析記事 • Feb 13
We're Not Very Worried About Rani Therapeutics Holdings' (NASDAQ:RANI) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...株主還元
| RANI | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | 32.5% | 1.6% | -1.4% |
| 1Y | 97.1% | 40.1% | 16.4% |
業界別リターン: RANI過去 1 年間で40.1 % の収益を上げたUS Pharmaceuticals業界を上回りました。
リターン対市場: RANI過去 1 年間で16.4 % の収益を上げたUS市場を上回りました。
価格変動
| RANI volatility | |
|---|---|
| RANI Average Weekly Movement | 14.7% |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: RANIの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: RANIの 週次ボラティリティ は過去 1 年間で39%から15%に減少しましたが、依然としてUS株の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2012 | 70 | Talat Imran | www.ranitherapeutics.com |
Rani Therapeutics Holdings, Inc.は、臨床段階のバイオセラピューティクス企業として事業を展開しており、米国において、患者、医師、および医療システムに対し、痛みを伴う注射に代わる選択肢として、生物学的製剤や医薬品を経口投与可能にする技術に注力しています。 同社は、オリゴヌクレオチド、ペプチド、タンパク質、抗体など、さまざまな薬物を送達するための薬剤非依存型の経口送達プラットフォーム「RaniPill」カプセルを開発しています。同社の製品パイプラインには、関節リウマチの治療を目的として前臨床試験段階にある抗TNF-α抗体「RT-105」、 肥満治療を目的として創薬段階にある「RT-116」、希少疾患治療を目的とした「RT-117」、および様々な炎症性疾患の治療を目的としたウステキヌマブのバイオシミラー「RT-111」が含まれています。 同社は、肥満治療薬「RT-114」の共同開発および商業化について、プロジェン株式会社と提携契約を締結している； 中外製薬株式会社とは、同社が血友病治療薬として開発中の化合物と、ヒト用経口投与デバイス「RaniPill HC」を組み合わせた「中外製品」の商業化について提携しています。また、PegBio Co., Ltd.とは、複数の新規候補薬にわたり肥満治療パイプラインを拡大するための研究開発提携を結んでいます。 Rani Therapeutics Holdings, Inc.は2012年に設立され、カリフォルニア州サンノゼに本社を置いている。
Rani Therapeutics Holdings, Inc. 基礎のまとめ
| RANI 基礎統計学 | |
|---|---|
| 時価総額 | US$85.60m |
| 収益（TTM） | -US$29.44m |
| 売上高(TTM) | US$3.17m |
28.3x
P/Sレシオ-3.0x
PER（株価収益率RANI は割高か？
公正価値と評価分析を参照収益と収入
| RANI 損益計算書（TTM） | |
|---|---|
| 収益 | US$3.17m |
| 売上原価 | US$0 |
| 売上総利益 | US$3.17m |
| その他の費用 | US$32.61m |
| 収益 | -US$29.44m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.29 |
| グロス・マージン | 100.00% |
| 純利益率 | -929.06% |
| 有利子負債／自己資本比率 | 0% |
RANI の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/22 18:07 |
| 終値 | 2026/07/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Rani Therapeutics Holdings, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9
| アナリスト | 機関 |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Edward Nash | Canaccord Genuity |
| Mitchell Kapoor | H.C. Wainwright & Co. |